We then validated these findings using in vivo animal models of PD, demonstrating not only protection against functional impairments associated with dopaminergic neuronal cell death in the SN but also a reduction in pathological α-synuclein aggregation in the brains of treated Line 61 mice. The gene discussed is SNCA; the disease is Parkinson disease.